SG Americas Securities LLC lowered its position in shares of Repligen Co. (NASDAQ:RGEN) by 83.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,153 shares of the biotechnology company’s stock after selling 20,288 shares during the quarter. SG Americas Securities LLC’s holdings in Repligen were worth $245,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Huntington National Bank bought a new position in Repligen in the first quarter valued at about $25,000. Mascoma Wealth Management LLC bought a new position in Repligen in the first quarter valued at about $41,000. Private Capital Group LLC grew its position in Repligen by 675.3% in the first quarter. Private Capital Group LLC now owns 721 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 628 shares during the last quarter. Enlightenment Research LLC bought a new position in Repligen in the fourth quarter valued at about $42,000. Finally, Parallel Advisors LLC grew its position in Repligen by 485.1% in the fourth quarter. Parallel Advisors LLC now owns 1,258 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 1,043 shares during the last quarter. 84.92% of the stock is owned by institutional investors.

Shares of NASDAQ:RGEN traded up $0.25 during midday trading on Monday, hitting $69.72. 3,447 shares of the stock were exchanged, compared to its average volume of 402,581. The stock has a market cap of $3.28 billion, a P/E ratio of 94.73, a price-to-earnings-growth ratio of 4.22 and a beta of 1.00. The company has a current ratio of 2.18, a quick ratio of 1.84 and a debt-to-equity ratio of 0.03. Repligen Co. has a 12 month low of $42.80 and a 12 month high of $72.45.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.28 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.02. The company had revenue of $60.63 million for the quarter, compared to analysts’ expectations of $55.09 million. Repligen had a return on equity of 6.35% and a net margin of 10.11%. The business’s quarterly revenue was up 35.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.17 earnings per share. As a group, equities analysts forecast that Repligen Co. will post 0.94 EPS for the current year.

Several analysts have recently weighed in on the company. Zacks Investment Research upgraded Repligen from a “hold” rating to a “strong-buy” rating and set a $80.00 price target on the stock in a report on Tuesday, May 14th. ValuEngine cut Repligen from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 4th. Finally, BidaskClub cut Repligen from a “hold” rating to a “sell” rating in a report on Tuesday, April 9th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Repligen presently has a consensus rating of “Buy” and an average target price of $64.20.

In related news, VP Ralf Kuriyel sold 2,240 shares of Repligen stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $58.53, for a total value of $131,107.20. Following the transaction, the vice president now directly owns 21,043 shares of the company’s stock, valued at $1,231,646.79. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Jon Snodgres sold 2,645 shares of Repligen stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $58.52, for a total value of $154,785.40. Following the completion of the transaction, the chief financial officer now directly owns 29,646 shares in the company, valued at $1,734,883.92. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,902 shares of company stock worth $2,627,287. Company insiders own 1.70% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “SG Americas Securities LLC Reduces Stake in Repligen Co. (RGEN)” was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/sg-americas-securities-llc-reduces-stake-in-repligen-co-rgen/3030290.html.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: Earnings Per Share (EPS)

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.